GW Pharma raises capital and certain shareholders cash out

GW Pharmaceuticals (GWPH) files to sell 1.2M American Depository Shares (ADS) and certain shareholders 500K ADSs. Each ADS represents ownership of 12 GWPH ordinary shares. Underwriters over-allotment is 255K ADSs. Proceeds to be used to fund pre-launch activities for Epidiolex in the U.S. including expanding the growing and manufacturing operations and build-up of inventory, the advancement of other early-stage pipeline opportunities (focused on orphan diseases) and general corporate purposes.

On June 16, 2014 the latest reported price/ADS was $77.25.


From other sites
Comments (6)
  • danr66
    , contributor
    Comments (23) | Send Message
    Why is this company classified as a MMJ co. when the ratio of cbd/thc in Epidiolex is 98% CBD vs. 0.14% THC? Doctors are traditionally reluctant to prescribe meds with higher levels of THC , they will want control over their prescriptions unless more high quality evidence is brought forth in the ongoing trials.
    18 Jun 2014, 07:59 AM Reply Like
  • mmk00
    , contributor
    Comments (4) | Send Message
    Your comment makes no sense. Doctors don't prescribe anything with THC. It is schedule one. You complain about high THC right after you say it is 98% CBD?
    18 Jun 2014, 08:37 PM Reply Like
  • Rumpel Pumpel
    , contributor
    Comments (436) | Send Message
    I dont think he is complaining about THC in it, he is just saying that it is a GOOD example for medicine, since the amount is so low, compared with other medicine made from the MJN-plant. We had a similar discussin on another article and I made the point about a tiny amount of THC in it, because the artcle stated there would be NONE THC in epidolex.


    danr66 can you please show me the link or tell me where you got the information about the CBD/THC ratio in Epidolex?


    I remain long in GWPH, I even added on the giant pullback on $64 levels and on the way back up around $74. The rest is long since last year. I think this news just prove how much people who are suffering from epilepsy need CBD medicine and it's beautiful to see how much efforts and how fast GW-Pharmaceuticals is making progress.
    19 Jun 2014, 01:19 AM Reply Like
  • danr66
    , contributor
    Comments (23) | Send Message
    My comment was based on the low am't of THC. I understand that CBD/THC are symbiotic in delivery of meds to brain receptors. My question was classification of company as a "pot stock" when it draws its strains from the cannabis plant. The end product is actually more of a bio-med, Source: Neurology Now magazine (June/July 2014) Medical Marijuana article by Darrach Dolan. The author quotes Dr. Orrin Devinsky of the NYU comprehensive Epilepsy Center, currently performing trials of Epidiolex. The American Academy of Neurology (AAN) undertook a review of these studies. The findings are published within the article.
    19 Jun 2014, 08:56 AM Reply Like
  • danr66
    , contributor
    Comments (23) | Send Message
 Dr. Devinsky was not involved in the AAN reviews.
    19 Jun 2014, 10:08 AM Reply Like
  • dan forbes
    , contributor
    Comments (39) | Send Message
    Sellers are the only smart ones, When they start getting flack from the DEA, watch out below. besides the fact that they have never made a profit. Too speculative for a long term hold, okay for a pump and dump.
    23 Jun 2014, 01:01 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs